MW 244.23 Da, Purity >98%. Low-molecular-weight kinase inhibitor of MAP-kinase interacting kinase-1 (MNK1) and MNK2 (IC50 values are 0.87 and 1.6 μM, respectively). Inhibits a range of other kinases (IC50 values in μM shown in brackets) including: CKI (0.51) Aurora B (2.5) DYRK3 (3.2) SGK1( 2.7) BRSK2 (1.1) and Lck (2.5).
522629-08-9
> 98%
Solid
244.23 Da
C11H9FN6
11644425
Synthetic
AAD20, AIK2, ARK-2, AURKB_HUMAN, AurB, Aurora 1, Aurora kinase B, Aurora- and Ipl1-like midbody-associated protein 1, Aurora-B, Aurora-related kinase 2, Aurora/IPL1-related kinase 2, BR serine/threonine kinase 2, BR serine/threonine-protein kinase 2, BRSK2_HUMAN, Brain selective kinase 2, Brain specific serine/threonine protein kinase 2, C11orf7, CKI-delta, CKId, CSNK 1D, Casein Kinase 1 delta, Casein kinase I delta isoform, Casein kinase I isoform delta, DKFZp686O15119, DYRK3_HUMAN, DYRK5, Double stranded RNA activated protein kinase;, Dual specificity tyrosine (Y) phosphorylation regulated kinase 3, Dual specificity tyrosine-phosphorylation-regulated kinase 3, E2AK2_HUMAN, EIF2AK1, EIF2AK2, ERR a, ERR-alpha, ERR1 protein, ERR1_HUMAN, ESRL 1, ESRR A, Estrogen receptor related 1, Estrogen receptor-like 1, Estrogen-related receptor alpha, Estrra, Eukaryotic translation initiation factor 2-alpha kinase 2, FLJ10358, G protein coupled receptor kinase 7, GAC, GAM, GLS, GLS1, GLSK_HUMAN, GPRK7, Glutaminase C, Glutaminase kidney isoform, Glutaminase phosphate activated, HCKID, HGNC:9437, IMD22, IPL1, Interferon inducible elF2 alpha kinase, Interferon-induced, double-stranded RNA-activated protein kinase, Interferon-inducible RNA-dependent protein kinase, K-glutaminase, KC1D_HUMAN, KGA, KIAA0838, L-glutamine amidohydrolase, LCK proto-oncogene, Src family tyrosine kinase, LCK_HUMAN, LSK, Lck p56, Leukocyte C-terminal Src kinase, Lymphocyte cell-specific protein-tyrosine kinase, Lymphocyte specific protein tyrosine kinase, MAP kinase interacting kinase 1, MAP kinase interacting serine threonine kinase, MAP kinase interacting serine threonine kinase 2, MAP kinase interacting serine threonine protein kinase 2, MAP kinase interacting serine/threonine kinase 1, MAP kinase signal-integrating kinase 1, MAP kinase signal-integrating kinase 2, MAP kinase-interacting serine/threonine-protein kinase 1, MAP kinase-interacting serine/threonine-protein kinase 2, MAPK interacting kinase 2, MAPK signal integrating kinase 1, MAPK signal integrating kinase 2, MGC126524, MITOGEN-ACTIVATED PROTEIN KINASE-INTERACTING SERINE/THREONINE KINASE 1, MKNK1_HUMAN, MKNK2_HUMAN, Membrane associated protein tyrosine kinase, Mitogen activated protein kinase interacting serine threonine kinase 2, NR3B1, Nuclear receptor subfamily 3 group B member 1, Oncogene lck, P1/eIF-2A protein kinase, PEN11B, PPP1R48, PPP1R83, PRKR, Protein YT16, Protein kinase CK1 delta, Protein kinase Dyrk3, Protein kinase RNA-activated, Protein kinase SAD1B, Protein kinase interferon inducible double stranded RNA dependent, Protein phosphatase 1 regulatory subunit 48, Protein phosphatase 1 regulatory subunit 83, Proto oncogene tyrosine protein kinase LCK, Proto-oncogene Lck, Putative map kinase interacting kinase, REDK, Regulatory erythroid kinase, SAD 1, SADA, STK-1, STK12, STK29, STK5, Serine threonine protein kinase Sgk1, Serine/theronine kinase 12, Serine/threonine kinase 29, Serine/threonine protein kinase BRSK2, Serine/threonine protein kinase TIK, Serine/threonine-protein kinase 12, Serine/threonine-protein kinase 29, Serine/threonine-protein kinase SAD-A, Serine/threonine-protein kinase aurora-B, Serum glucocorticoid regulated kinase, Steroid hormone receptor ERR1, T cell-specific protein-tyrosine kinase, T lymphocyte specific protein tyrosine kinase p56lck, Tyrosine protein kinase EIF2AK2, Tyrosine-protein kinase Lck, YT 16, eIF-2A protein kinase 2, estrogen receptor related receptor alpha, hERR1, hYAK3 2, mitochondrial, p56(LSTRA) protein tyrosine kinase, p56-LCK, p68 kinase, pp58 lck
MW 244.23 Da, Purity >98%. Low-molecular-weight kinase inhibitor of MAP-kinase interacting kinase-1 (MNK1) and MNK2 (IC50 values are 0.87 and 1.6 μM, respectively). Inhibits a range of other kinases (IC50 values in μM shown in brackets) including: CKI (0.51) Aurora B (2.5) DYRK3 (3.2) SGK1( 2.7) BRSK2 (1.1) and Lck (2.5).
522629-08-9
> 98%
Solid
244.23 Da
C11H9FN6
11644425
Synthetic
Soluble in DMSO to 100 mM.
N3-(4-fluorophenyl)-1h-pyrazolo[3,4-d]pyrimidine-3,4-diamine
Low-molecular-weight kinase inhibitor of MAP-kinase interacting kinase-1 (MNK1) and MNK2 (IC50 values are 0.87 and 1.6 μM, respectively). Inhibits a range of other kinases (IC50 values in μM shown in brackets) including: CKI (0.51) Aurora B (2.5) DYRK3 (3.2) SGK1( 2.7) BRSK2 (1.1) and Lck (2.5).
C1=CC(=CC=C1NC2=C3C(=NC=NC3=NN2)N)F
InChI=1S/C11H9FN6/c12-6-1-3-7(4-2-6)16-11-8-9(13)14-5-15-10(8)17-18-11/h1-5H,(H4,13,14,15,16,17,18)
UQPMANVRZYYQMD-UHFFFAOYSA-N
3-N-(4-fluorophenyl)-2H-pyrazolo[3,4-d]pyrimidine-3,4-diamine
Ambient - Can Ship with Ice
+4°C
+4°C
The product can be stored for up to 12 months
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
2D chemical structure image of ab120365, CGP 57380, MNK inhibitor
Anti-eIF4E (phospho S209) antibody [EP2151Y] ab76256 staining eIF4E (phospho S209) in serum starved HEK193 cells treated with CGP 57380 (ab120365), by ICC/IF. Decrease in eIF4E (phospho S209) expression correlates with increased concentration of CGP 57380, as described in literature.
The cells were incubated at 37°C for 1h in media containing different concentrations of ab120365 (CGP 57380) in DMSO, fixed with 100% methanol for 5 minutes at -20°C and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with Anti-eIF4E (phospho S209) antibody [EP2151Y] ab76256 (1/100 dilution) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 goat anti-rabbit polyclonal antibody (Goat Anti-Rabbit IgG H&L (DyLight® 488) preadsorbed ab96899) at 1/250 dilution was used as the secondary antibody. Nuclei were counterstained with DAPI and are shown in blue.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com